Skip navigation

MCNEIL HEALTHCARE

OLYGRIP DAY 500/60 MG AND OLYGRIP NIGHT 500/25 MG

Product from
Farmacia
1 pc
RON 19.79 RON 19.79 /pc

Delivery within 3 hours


You're reading an Auto-translation.

Therapeutic indications

Olygrip Day and Night tablets are indicated for the short-term symptomatic treatment of nasal and sinus congestion, associated with cold and flu symptoms such as pain, neuralgia, and/or fever, only in conjunction with symptoms that appear in the evening at bedtime, causing difficulty falling asleep.

Olygrip is intended for use in adults and adolescents aged between 15 and 17 years.

 

Method of administration

Oral administration

Adults and adolescents aged at least 15 years:

Four tablets should be administered daily.

One white tablet (paracetamol and pseudoephedrine) should be administered every 4-6 hours during the day (one tablet in the morning, one at noon, and one in the afternoon). Do not take more than 3 white day tablets within 24 hours.

One blue tablet (paracetamol and diphenhydramine) should be administered in the evening, before bedtime.

Do not take the night tablets during the day.

 

Elderly:

The maximum daily dose should not exceed 60 mg/kg/day (up to a maximum of 2 g paracetamol per day) in the following situations, unless otherwise indicated by a doctor:

  • Weight less than 50 kg
  • Chronic alcoholism
  • Dehydration
  • Chronic malnutrition

Contraindications

Olygrip is contraindicated in patients with:

Hypersensitivity to paracetamol, pseudoephedrine, diphenhydramine, or any of the excipients listed in the leaflet. Concomitant use of other sympathomimetic decongestants, beta-blockers, or monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOI treatment.
Concomitant use of MAOIs may cause an increase in blood pressure or a hypertensive crisis.


  • Cardiovascular diseases, including arterial hypertension
  • Diabetes mellitus
  • Pheochromocytoma
  • Hyperthyroidism
  • Closed-angle glaucoma
  • Severe renal insufficiency
  • Urinary retention in patients at risk of respiratory failure.

Age: 15 years +

 

Page updated on: 19.01.2023